Cd11b and Cd56 as Prognostic Markers in Acute Myeloid Leukemia

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03283228

Enrollment

Registered

2017-09-14

Start date

2017-12-01

Completion date

2019-10-01

Last updated

2017-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adult Acute Myeloid Leukemia

Brief summary

1. Detect the expression of marker CD56 and CD11b in newly diagnosed cases of adult AML. 2. Study correlation between CD56 and CD11b expression with haematological parameters in cases of adult AML.

Detailed description

1. CD11b expression level is a prognostic biomarker for AML patient. CD11b positivity could predict a poor prognosis for AML patients. 2. CD56 antigen expression, an inexpensive, easy to detect and reproduce index, is closely related to the prognosis of AML patients

Interventions

DIAGNOSTIC_TESTCd11b and Cd56 markers

The expression of CD11b and CD56 in newly diadnosed cases of AML

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to 50 Years

Healthy volunteers

Inclusion criteria

Anew diagnosis cases of adult AML

Exclusion criteria

1. Pediatric AML . 2. follow up cases of adult AML

Design outcomes

Primary

Measure	Time frame	Description
CD11b and CD56 marker	24 month	Detect the expression of marker CD56 and CD11b in newly diagnosed cases of adult AML.

Contacts

Primary ContactShaaban Helal, PHD

Elhelal2007@gmail.com01005688567

Backup ContactEman Salah Eldin, lecture

Emansalah.eldin@yahoo.com01028030966

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026